SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as reports surface of unsolicited takeover interest from rivals, some eyeing the entire company while others target specific assets like Venmo or Braintree following its significant stock slump. The community is actively debating potential buyers and buyout prices, largely driven by the belief that the fintech giant is fundamentally undervalued given its substantial free cash flow and ongoing share buyback program.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is a major talking point as its impending earnings report follows recent news of a 12% workforce reduction, fueling intense community debate over the stock's persistent new all-time lows and the company's financial outlook in the competitive EV sector.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending amid an industry-wide selloff in cybersecurity stocks, driven by investor concerns following Anthropic's new "Claude Code Security" tool. However, many in the community and analysts argue this is an overreaction, asserting that AI will enhance, not replace, the critical enterprise security solutions provided by companies like CrowdStrike.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is experiencing heightened trading activity following the FDA approval of its BYSANTI drug for bipolar I disorder and schizophrenia, which notably secured New Chemical Entity status and patent protection until 2044. The community is buzzing with discussions about the stock's significant undervaluation, pointing to its strengthened pipeline and past rejected buyout offers, fueling expectations for a substantial re-rating and potential M&A interest from larger pharmaceutical companies.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting overwhelmingly positive Phase 2 clinical trial results for sonelokimab in axial spondyloarthritis, demonstrating significant efficacy and potential disease modification ahead of its Investor Day. Despite this "game-changing" data and the company's strong cash runway, the community is actively discussing market "sell the news" behavior and perceived manipulation amidst significant short interest.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point as President Trump files a $5 billion lawsuit against the bank and CEO Jamie Dimon, alleging politically motivated account closures, a move that follows Dimon's public criticism of Trump's proposed credit card rate cap and fuels community debate over broader financial sector pressures.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF ($IGV) is experiencing a significant sell-off and hitting new lows, fueled by widespread community fear that Anthropic's Claude AI tools will disrupt and replace traditional software. This "SaaS-pocalypse" is sparking intense debate among investors over whether the market's aggressive reaction is an overblown narrative or a fundamental threat.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as the broader software sector sell-off weighs heavily, prompting community debate on whether market fears about AI's disruptive potential are irrationally impacting this AI-driven marketing platform ahead of its highly anticipated earnings report. Despite a consistent streak of financial beats and a proprietary data "moat", investors are grappling with extreme volatility and a perceived disconnect between strong fundamentals and current stock performance.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is facing intense selling pressure, hitting new lows, as the cybersecurity sector grapples with fears that AI tools like Anthropic's Claude Code Security could disrupt existing solutions, prompting community debate between panic selling and 'buy the dip' opportunities ahead of its earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as investors and the community react to former President Trump's re-imposition of higher tariffs following a Supreme Court decision, fueling debate over economic stability and market impact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$EDAP 

https://youtu.be/DObcQVY4s5w?si=LTlNMNzzvR_d1t4l

Interesting discussion in focal therapy, he mentions all the ongoing trials with HIFU and mentions the HIFUSA trial.  I mentioned this trial awhile ago cause I was wanting an update and it seems it ends in June of this year and the preliminary results look good as it shows people that have HIFU early on instead of active surveillance have a 50% better chance of avoiding radical treatments down the line while still maintaining QoL

That would be big if focal therapy takes place of active surveillance as a first line measure against most early cancers if you can avoid radical treatments downstream and would look good for insurances that want to prevent those costs down the line too

Georges8792

Rich

Ray Tarke

Sébastien Crouzet, MD, PhD, Urology Department, Edouard Herriot Hospital, Claude Bernard University, Lyon, France, reviews multiple levels of evidence comparing focal high-intensity focused ultrasound (HIFU) or subtotal whole-gland HIFU with radical prostatectomy. He begins with the French national trial comparing HIFU to radical prostatectomy. After age-adjusted analysis, HIFU was considered non-inferior to salvage therapy.

YouTube

Focal Therapy vs Radical Treatment for Prostate Cancer

StockTwits for iOS

EDAP TMS SA



Interesting discussion in focal therapy, he mentions all the ongoing trials with HIFU and mentions the HIFUSA trial.  I mentioned this trial awhile ago cause I was wanting an update and it seems it ends in June of this year and the preliminary results look good as it shows people that have HIFU early on instead of active surveillance have a 50% better chance of avoiding radical treatments down the line while still maintaining QoL

That would be big if focal therapy takes place of active surveillance as a first line measure against most early cancers if you can avoid radical treatments downstream and would look good for insurances that want to prevent those costs down the line too